Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study FILRI-CHOP

View Full Paper
Ask AI
Bookmark
Share

Authors

CPChiara PaganiELElisa LucchiniAMA Merli

Discussion

Loading...

Member takes

Overview

Phase II trial found ibrutinib plus R-CHOP improved progression-free survival in young high-risk ABC-DLBCL patients, indicating safety and efficacy.

Key Points

  • To assess the safety and efficacy of ibrutinib combined with R-CHOP in untreated young patients with ABC-DLBCL.
  • Prospective, multicenter, single-arm, phase II trial
  • Enrolled patients aged 18-65 with ABC-DLBCL and IPI ≥2
  • Patients received R-CHOP followed by ibrutinib maintenance if partial response was achieved
  • Overall response rate (ORR) was 90.7% after 4 cycles
  • Achieved 21.3% complete response and 69.3% partial response
  • Neutropenia was the most common adverse event, with manageable safety profile

Cite This Study

Pagani et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cfdbhttps://doi.org/10.1182/blood-2025-55
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib plus R-CHOP versus R-CHOP as first-line therapy in double-expressor DLBCL: A multicenter, propensity score matched retrospective study2025
  2. 2A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial2025
  3. 3Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study2025
  4. 4Promising efficacy of BI-1206, an antibody targeting FcγRIIB in combination with rituximab and acalabrutinib in R/R NHL patients NHL2025
  5. 5Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL)2025 · 1 citations